Organigram extends innovation investment in Phylos

Organigram (OGI) Global announced the expansion of its innovation investment in Phylos Bioscience. Through an amended loan and product agreement, Organigram gains priority access to Phylos’ autoflower genetics pipeline, including preferential economic terms and long-term rights in its international markets, establishing a foundation for product differentiation and growth in recreational and medical markets. Under the amended product agreement, Organigram receives five-year exclusivity on its chosen autoflower cultivars across international markets, including Canada, Australia, the UK, Germany, and Israel, with the ability to add new exclusive territories as it expands globally. Annual portfolio reviews will maintain exclusivity only for commercially relevant cultivars, maximising flexibility and strengthening Organigram’s international product differentiation strategy as it enters high-value medical markets. Under the terms of the amended loan agreement, Organigram will consolidate its existing investment with a new $3M advance, resulting in a combined total loan principal of $10M. The loan matures on May 25, 2028, and is subject to conversion or other resolution mechanisms under the amended agreement.